Mark Fernandez, MD
Ophthalmology · Norfolk, VANPI 1881860013
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $714, 5.2 times the $138 reported in 2019.
Across 113 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$520
- Alcon$348
- Amgen$307
- Sun Pharmaceutical Industries Inc.$160
- Dompe US, Inc.$130
- Tarsus Pharmaceuticals, Inc.$116
- plus $858 from 16 others
What the payments were for
- Food & beverage$2,440100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $520 |
| Alcon | 15 | $348 |
| Amgen(2 entities) | 13 | $307 |
| Sun Pharmaceutical Industries Inc. | 8 | $160 |
| Dompe US, Inc. | 6 | $130 |
| Tarsus Pharmaceuticals, Inc. | 4 | $116 |
| Mallinckrodt Hospital Products Inc. | 3 | $96 |
| Oyster Point Pharma, Inc. | 5 | $87 |
| AstraZeneca | 4 | $86 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $84 |
| Harrow Eye, LLC | 3 | $76 |
| Kala Pharmaceuticals, Inc. | 4 | $70 |
| Thea Pharma Inc. | 3 | $66 |
| Novartis | 3 | $55 |
| Aerie Pharmaceuticals, Inc. | 3 | $38 |
| Bausch & Lomb Americas Inc. | 2 | $38 |
| Biotissue Holdings Inc. | 2 | $32 |
| UCB, Inc. | 1 | $30 |
| Glaukos Corporation | 1 | $30 |
| Rxsight Inc | 1 | $28 |
| NEW World Medical,inc. | 1 | $22 |
| Omeros Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$107
How this compares
$2,440 in reported general payments places this provider in the 70th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 36 | $39,386 |
| XiidraLifitegrast | 16 | $21,809 |
| Prednisolone Acetate | 331 | $15,447 |
| Cyclosporine | 14 | $8,333 |
| RhopressaNetarsudil Mesylate | 11 | $7,069 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 38 | $6,563 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $6,126 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $4,129 |
| Latanoprost | 359 | $3,926 |
| MoxifloxacinMoxifloxacin Hcl | 110 | $2,122 |
| Ketorolac Tromethamine | 116 | $2,067 |
| Brimonidine Tartrate | 57 | $1,378 |
| ValacyclovirValacyclovir Hcl | 52 | $1,194 |
| Timolol Maleate | 106 | $882 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $520 | $45,51151 claims |
| Bausch & Lomb Americas Inc.Xiidra | $38 | $21,80916 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $38 | $7,06911 claims |
| AlconSimbrinza | $348 | $4,12916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Kapil KapoorNorfolk$64K
- Albert CheungNorfolk$23K
- Samantha DewundaraNorfolk$19K
- Arielle SpitzeNorfolk$10K
- Rohit AdyanthayaNorfolk$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.